Translational pharmacokinetics: Current issues with newer antidepressants

  title={Translational pharmacokinetics: Current issues with newer antidepressants},
  author={C. Lindsay DeVane},
  journal={Depression and Anxiety},
  • C. DeVane
  • Published 1998
  • Biology, Medicine
  • Depression and Anxiety
Translational pharmacokinetics involves the application of our knowledge of drug metabolism and disposition to clinical practice. The newer antidepressants are a diverse group of compounds in terms of pharmacokinetic properties and the potential for participation in drug interactions. Clinical questions have been taken into the laboratory and the results back into the clinic. Unfortunately, several issues are unresolved. The clinical significance of the stereochemistry of the newer… 

Population pharmacokinetic analysis of drug–drug interactions among risperidone, bupropion, and sertraline in CF1 mice

It is suggested that pharmacokinetic interactions exist among these three psychoactive drugs involving inhibition of drug metabolizing enzymes and/or P-gp and other drug transporters present in the BBB.

Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.

Fluoxetine has shown superior efficacy compared with placebo in the treatment of depression in patients with HIV/AIDS, diabetes mellitus or stroke; however, it has not significantly improved depressive symptoms versus placebo in patientsWith cancer, and is safer in overdose than TCAs and monoamine oxidase inhibitors.

Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone in Healthy Volunteers

It is demonstrated in vivo that, unlike nefazodone, venlafaxine, sertraline, and fluoxetine do not possess significant metabolic inductive or inhibitory effects on CYP3A4.

Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.

Considering in vitro and available clinical data, desvenlafaxine and venlafxine appear to have low potential for pharmacokinetic drug-drug interactions via inhibiting the metabolic clearance of concomitant drugs that are substrates of various CYP enzymes, in particular CYP2D6.

Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder

Dose escalation of SSRIs is equivocally supported by evidence of randomised controlled trials; methodological difficulties in the studies may account for this lack of evidence.

Dose-escalation in the picture : pharmacological and imaging studies in depression

This dissertation aims to provide a history of web exceptionalism from 1989 to 2002, a period chosen in order to explore its roots as well as specific cases up to and including the year in which descriptions of “Web 2.0” began to circulate.

Fluoxetine : A review of its use in anxiety disorders and mixed anxiety and depression

Fluoxetine is effective in the short term treatment of panic, social anxiety, post-traumatic stress and obsessive-compulsive disorders, and may be effective in patients experiencing anxiety symptoms and depression.